FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024689574> ?p ?o ?g. }

• W2024689574 abstract "Background: BIIB021 is an oral, fully synthetic heat shock protein 90 inhibitor (Hsp90i) that selectively and potently inhibits the molecular chaperone Hsp90, thereby preventing proper assembly of oncogenic proteins such as HER2. Methods: The safety and tolerability of escalating doses of BIIB021 taken by mouth twice weekly (BIW) in combination with fixed doses of trastuzumab (8 mg/kg loading dose, then 6 mg/kg IV every 3 weeks [Q3W]) were determined using a 3+3 dose escalation design with dose expansion at MTD in patients with advanced HER2+ metastatic breast cancer (MBC) refractory to trastuzumab-based therapy. Pharmacokinetics (PK), efficacy, and pharmacodynamics were also assessed. Results: Thirty patients received BIIB021 within 4 dose groups: 200 (n = 3), 400 (n = 5), 600 (n = 20), and 700 mg (n = 2) BIW plus trastuzumab Q3W. All patients were female and median age was 58 years. All patients had ≥1 prior systemic therapy (median 8) and ≥1 prior treatment with trastuzumab (median 4) for HER2+ MBC. Median time on study was 45 days (range 8-213). Twenty (67%) patients withdrew due to progressive disease, 4 (13%) withdrew consent, 3 (10%) withdrew due to adverse events (AEs), and 1 was withdrawn by the Investigator. The MTD for BIIB021 with trastuzumab is 600 mg BIW. Dose-limitingtoxicities were Grade (G) 3 diarrhea (2/20 patients at 600 mg) and G4 aphasia (1/2 patients at 700 mg). The event of aphasia was serious, drug-related, and considered by the Sponsor to be a complex partial seizure. An additional drug-related SAE was G3 hypopituitarism reported for 1 patient at 600 mg. All AEs regardless of relationship occurring in ≥20% of patients included nausea (70%), dizziness (63%), fatigue (63%), diarrhea (57%), vomiting (50%), headache (37%), rash (33%), constipation (30%), hot flush (27%), chills (23%), back pain (23%), UTI (23%), and dyspnea (20%). PK analyses indicated dose-dependent increases in BIIB021 plasma C max and AUC, consistent with previous studies. C max and AUC did not change from Day 1 to Day 22 for any dose group. Terminal half-life ranged from 1-2 hours and T max from 0.5-1.5 hours. Trastuzumab PK was consistent with the product label. Significant induction of Hsp70 (7.5-fold increase) in PBMCs and/or inhibition of serum HER2-ECD (20% decrease) were observed in 50% of evaluable patients (n = 25). A >50% decrease in total circulating tumor cells (CTC) and in HER2+ CTC was observed in patients with >5 CTC at baseline. Antitumor activity was observed in 2 patients (400 and 600 mg) who experienced confirmed partial response (PR) by RECIST. These 2 patients also had metabolic PR (>25% reduction in SUVmax by FDG-PET) and significant changes in Hsp70 and HER2-ECD biomarkers. One confirmed PR is ongoing (>6 months). Conclusions: BIIB021 was tolerated at doses ≥600 mg BIW plus trastuzumab Q3W without apparent alteration in the PK profile of either drug. Consistent with previous combination studies with other Hsp90i in trastuzumab-refractory HER2+ MBC, antitumor activity was observed (2 confirmed PRs) along with significant changes in biomarker levels. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P3-14-02." @default.
• W2024689574 created "2016-06-24" @default.
• W2024689574 creator A5008343334 @default.
• W2024689574 creator A5024606959 @default.
• W2024689574 creator A5039685591 @default.
• W2024689574 creator A5040405589 @default.
• W2024689574 creator A5064706203 @default.
• W2024689574 creator A5065640278 @default.
• W2024689574 creator A5083373965 @default.
• W2024689574 creator A5085569847 @default.
• W2024689574 creator A5088739383 @default.
• W2024689574 creator A5090481533 @default.
• W2024689574 date "2010-12-15" @default.
• W2024689574 modified "2023-09-26" @default.
• W2024689574 title "Abstract P3-14-02: Phase 1 Dose-Escalation Study of the Heat Shock Protein 90 Inhibitor BIIB021 with Trastuzumab in HER2+ Metastatic Breast Cancer" @default.
• W2024689574 doi "https://doi.org/10.1158/0008-5472.sabcs10-p3-14-02" @default.
• W2024689574 hasPublicationYear "2010" @default.
• W2024689574 type Work @default.
• W2024689574 sameAs 2024689574 @default.
• W2024689574 citedByCount "9" @default.
• W2024689574 countsByYear W20246895742012 @default.
• W2024689574 countsByYear W20246895742013 @default.
• W2024689574 countsByYear W20246895742014 @default.
• W2024689574 countsByYear W20246895742015 @default.
• W2024689574 countsByYear W20246895742016 @default.
• W2024689574 countsByYear W20246895742017 @default.
• W2024689574 crossrefType "proceedings-article" @default.
• W2024689574 hasAuthorship W2024689574A5008343334 @default.
• W2024689574 hasAuthorship W2024689574A5024606959 @default.
• W2024689574 hasAuthorship W2024689574A5039685591 @default.
• W2024689574 hasAuthorship W2024689574A5040405589 @default.
• W2024689574 hasAuthorship W2024689574A5064706203 @default.
• W2024689574 hasAuthorship W2024689574A5065640278 @default.
• W2024689574 hasAuthorship W2024689574A5083373965 @default.
• W2024689574 hasAuthorship W2024689574A5085569847 @default.
• W2024689574 hasAuthorship W2024689574A5088739383 @default.
• W2024689574 hasAuthorship W2024689574A5090481533 @default.
• W2024689574 hasConcept C111113717 @default.
• W2024689574 hasConcept C112705442 @default.
• W2024689574 hasConcept C121608353 @default.
• W2024689574 hasConcept C126322002 @default.
• W2024689574 hasConcept C141071460 @default.
• W2024689574 hasConcept C143998085 @default.
• W2024689574 hasConcept C197934379 @default.
• W2024689574 hasConcept C2775930923 @default.
• W2024689574 hasConcept C2778375690 @default.
• W2024689574 hasConcept C2779786085 @default.
• W2024689574 hasConcept C530470458 @default.
• W2024689574 hasConcept C71924100 @default.
• W2024689574 hasConcept C90924648 @default.
• W2024689574 hasConcept C98274493 @default.
• W2024689574 hasConceptScore W2024689574C111113717 @default.
• W2024689574 hasConceptScore W2024689574C112705442 @default.
• W2024689574 hasConceptScore W2024689574C121608353 @default.
• W2024689574 hasConceptScore W2024689574C126322002 @default.
• W2024689574 hasConceptScore W2024689574C141071460 @default.
• W2024689574 hasConceptScore W2024689574C143998085 @default.
• W2024689574 hasConceptScore W2024689574C197934379 @default.
• W2024689574 hasConceptScore W2024689574C2775930923 @default.
• W2024689574 hasConceptScore W2024689574C2778375690 @default.
• W2024689574 hasConceptScore W2024689574C2779786085 @default.
• W2024689574 hasConceptScore W2024689574C530470458 @default.
• W2024689574 hasConceptScore W2024689574C71924100 @default.
• W2024689574 hasConceptScore W2024689574C90924648 @default.
• W2024689574 hasConceptScore W2024689574C98274493 @default.
• W2024689574 hasLocation W20246895741 @default.
• W2024689574 hasOpenAccess W2024689574 @default.
• W2024689574 hasPrimaryLocation W20246895741 @default.
• W2024689574 hasRelatedWork W1563031684 @default.
• W2024689574 hasRelatedWork W1970460458 @default.
• W2024689574 hasRelatedWork W1988675578 @default.
• W2024689574 hasRelatedWork W2022531767 @default.
• W2024689574 hasRelatedWork W2024524048 @default.
• W2024689574 hasRelatedWork W2042985720 @default.
• W2024689574 hasRelatedWork W2043832565 @default.
• W2024689574 hasRelatedWork W2085961273 @default.
• W2024689574 hasRelatedWork W2112417555 @default.
• W2024689574 hasRelatedWork W2114032749 @default.
• W2024689574 hasRelatedWork W2118012556 @default.
• W2024689574 hasRelatedWork W2158780525 @default.
• W2024689574 hasRelatedWork W2171708713 @default.
• W2024689574 hasRelatedWork W2243445374 @default.
• W2024689574 hasRelatedWork W2268504878 @default.
• W2024689574 hasRelatedWork W2519006788 @default.
• W2024689574 hasRelatedWork W2563050743 @default.
• W2024689574 hasRelatedWork W2593411190 @default.
• W2024689574 hasRelatedWork W2742058787 @default.
• W2024689574 hasRelatedWork W2809182682 @default.
• W2024689574 isParatext "false" @default.
• W2024689574 isRetracted "false" @default.
• W2024689574 magId "2024689574" @default.
• W2024689574 workType "article" @default.